A5014321150- Prostate Cancer Treatment and Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer survivorship and care
- Cancer Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Erythropoietin and Anemia Treatment
- Ovarian cancer diagnosis and treatment
- Renal and related cancers
- Breast Cancer Treatment Studies
- Management of metastatic bone disease
- Renal cell carcinoma treatment
- HER2/EGFR in Cancer Research
- Bone health and treatments
- Childhood Cancer Survivors' Quality of Life
- Immunotherapy and Immune Responses
- Pain Management and Opioid Use
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Neutropenia and Cancer Infections
- PARP inhibition in cancer therapy
Hospital Universitario de Guadalajara
2014-2024
Hospital Arnau de Vilanova
2013
Complejo Hospitalario Universitario de Albacete
2013
Centro Oncológico de Galicia
2013
GEICAM – Spanish Breast Cancer Group
2013
Hospital Xeral Calde
2006
Hospital Nuestra Señora de Alarcos
2005-2006
American Association For Cancer Research
2003
Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or surgery, hypercalcaemia. Patients with experience pain, functional impairment have a negative impact on their quality life. Several imaging techniques available for diagnosis this disease. Bone-targeted therapies include...
Androgen deprivation treatment was the only available for metastatic prostate cancer until recently, with docetaxel as a proven survival benefit in castration-resistant (CRPC). Several drugs have been approved disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More and abiraterone moved to hormone-sensitive setting, achieving better patient survival. The purpose of this article is define state art carcinoma.
Fatigue is a symptom with relevant impact on the daily lives of cancer patients and gaining importance as an outcome measure. The Perform Questionnaire (PQ) new scale originally developed among Spanish-speaking for assessment perception beliefs about fatigue in patients.An observational longitudinal multicenter study was carried out fatigue. Fatigue-specific measures (FACT-F), generic health-related quality-of-life (NHP), PQ were gathered at baseline 3 months later. Feasibility, reliability...
Abstract Background Despite effective analgesic therapy, inadequate pain control is frequently perceived by patients and caregivers. Aims To assess satisfaction with management of in cancer patients. Methods Between J anuary M ay 2007, a cross‐sectional multicentre study was conducted 64 edical O ncology D epartments throughout S pain. A total 525 outpatients oncological diseases completed questionnaire demographic data, characteristics intensity pain, perceptions attitudes towards at the...
Docetaxel and irinotecan chemotherapy have shown good efficacy in the treatment of advanced oesophago-gastric cancer. This randomised phase II study evaluated toxicity profile two non-platinum docetaxel-based doublet regimens Chemotherapy-naïve patients with cancer were to receive either 3-weekly DI (docetaxel 60 mg m−2 plus 250 (Day 1)) or DF 85 1) followed by 5-fluorouracil 750 per day as a continuous infusion (Days 1–5)). A total received (n=42) (n=43). The primary endpoint was overall...
Androgen deprivation treatment is the current standard first-line for metastatic prostate cancer. For several years, docetaxel was only with a proven survival benefit castration-resistant cancer (CRPC). Since became of care men symptomatic (CRPC), three virtual spaces, and drug development in CPRC, have emerged: pre-docetaxel, combinations post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide radium-223 been approved pre- or post-docetaxel setting CRPC during last few years....
The PERFORM Questionnaire is a 12-item scale developed for assessing fatigue in cancer patients the clinical practice. It has advantages over other tools that it short and includes beliefs attitudes of about fatigue. was psychometrically validated with without anemia.We evaluated usefulness to measure large study focusing exclusively on anemic patients.This an observational, multicenter, prospective, 3-month hemoglobin (Hb)≤11 g/dl. Fatigue assessed using questionnaire. overall score ranges...
Recently, metastatic renal cell carcinoma (mRCC) treatment has changed dramatically with the onset of new therapies against molecular targets replacing immunotherapy as standard treatment. We report case a 49-year-old patient moderately differentiated clear without extracapsular extension who underwent radical nephrectomy. Eight months after surgery, he developed thyroid metastasis which was also treated surgically hemithyroidectomy. Seventy-five nephrectomy, presented an upper...
Background: The quality of cancer care has become a priority for health systems. goal this research was to develop set evidence-based indicators (QIs) organization, palliative care, and colorectal, breast, lung cancers introducing system benchmarking in Spain. Methods: A comprehensive literature search performed identify potential QIs. An expert panel (the promotion group) 9 oncologists identified evaluated them. Delphi process involving 58 physicians used rank QIs by clinical relevance...
Objective: Anaemia is common in cancer patients treated with chemotherapy. Darbepoetin alfa (DA) the only erythropoiesis-stimulating protein approved for administration at weekly and every-three-week intervals receiving This article investigates effectiveness, tolerability effect on fatigue of DA.Methods: Prospective, observational study performed 30 Spanish centres. Eligible were ≥ 18 years age, anaemic (haemoglobin [Hb] ≤ 11 g/dL), non-myeloid malignancies, DA (150 μg) was administered a...